Melissa A Lyle1, Seethalakshmi R Iyer1, Margaret M Redfield1, Yogesh N V Reddy1, G Michael Felker2, Thomas P Cappola3, Adrian F Hernandez2, Christopher G Scott4, John C Burnett1, Naveen L Pereira5. 1. Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota. 2. Division of Cardiology, Duke Clinical Research Institute, Durham, North Carolina. 3. Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 4. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota. 5. Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota. Electronic address: Pereira.naveen@mayo.edu.
Abstract
BACKGROUND: In heart failure with reduced ejection fraction (HFrEF), elevated soluble neprilysin (sNEP) levels are associated with an increased risk of cardiovascular death, and its inhibition with sacubitril/valsartan has improved survival. OBJECTIVES: This study sought to determine the relevance of sNEP as a biomarker in heart failure with preserved ejection fraction (HFpEF) and to compare circulating sNEP levels in patients with HFpEF with normal controls. METHODS: A case-control study was performed in 242 symptomatic patients with HFpEF previously enrolled in the Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction (RELAX) and Nitrates's Effect on Activity Tolerance in Heart Failure With Preserved Ejection (NEAT-HFpEF) clinical trials and 891 asymptomatic subjects without HF or diastolic dysfunction (confirmed by NT-proBNP levels <200 pg/ml and echocardiography) who were enrolled in the Prevalence of Asymptomatic Left Ventricular Dysfunction study. sNEP was measured using a sandwich enzyme-linked immunosorbent assay (ELISA) in all subjects. RESULTS:Overall, sNEP levels were lower in HFpEF compared with controls (3.5 ng/ml; confidence interval [CI]: 2.5 to 4.8 vs. 8.5 ng/ml; CI: 7.2 to 10.0; p < 0.001). After adjusting for age, gender, body mass index (BMI), and smoking history, mean sNEP levels were also lower in HFpEF compared with controls (4.0 ng/ml [CI: 2.7 to 5.4] vs. 8.2 ng/ml [CI: 6.8 to 9.7]; p = 0.002). The cohorts were propensity matched based on age, BMI, diabetes, hypertension, smoking history, and renal function, and sNEP levels remained lower in HFpEF compared with controls (median 2.4 ng/ml [interquartile range: 0.6 to 27.7] vs. 4.9 ng/ml [interquartile range: 1.2 to 42.2]; p = 0.02). CONCLUSIONS: Patients with HFpEF on average have significantly lower circulating sNEP levels compared with controls. These findings challenge our current understanding of the complex biology of circulating sNEP in HFpEF.
RCT Entities:
BACKGROUND: In heart failure with reduced ejection fraction (HFrEF), elevated soluble neprilysin (sNEP) levels are associated with an increased risk of cardiovascular death, and its inhibition with sacubitril/valsartan has improved survival. OBJECTIVES: This study sought to determine the relevance of sNEP as a biomarker in heart failure with preserved ejection fraction (HFpEF) and to compare circulating sNEP levels in patients with HFpEF with normal controls. METHODS: A case-control study was performed in 242 symptomatic patients with HFpEF previously enrolled in the Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction (RELAX) and Nitrates's Effect on Activity Tolerance in Heart Failure With Preserved Ejection (NEAT-HFpEF) clinical trials and 891 asymptomatic subjects without HF or diastolic dysfunction (confirmed by NT-proBNP levels <200 pg/ml and echocardiography) who were enrolled in the Prevalence of Asymptomatic Left Ventricular Dysfunction study. sNEP was measured using a sandwich enzyme-linked immunosorbent assay (ELISA) in all subjects. RESULTS: Overall, sNEP levels were lower in HFpEF compared with controls (3.5 ng/ml; confidence interval [CI]: 2.5 to 4.8 vs. 8.5 ng/ml; CI: 7.2 to 10.0; p < 0.001). After adjusting for age, gender, body mass index (BMI), and smoking history, mean sNEP levels were also lower in HFpEF compared with controls (4.0 ng/ml [CI: 2.7 to 5.4] vs. 8.2 ng/ml [CI: 6.8 to 9.7]; p = 0.002). The cohorts were propensity matched based on age, BMI, diabetes, hypertension, smoking history, and renal function, and sNEP levels remained lower in HFpEF compared with controls (median 2.4 ng/ml [interquartile range: 0.6 to 27.7] vs. 4.9 ng/ml [interquartile range: 1.2 to 42.2]; p = 0.02). CONCLUSIONS:Patients with HFpEF on average have significantly lower circulating sNEP levels compared with controls. These findings challenge our current understanding of the complex biology of circulating sNEP in HFpEF.
Authors: Garvan C Kane; Barry L Karon; Douglas W Mahoney; Margaret M Redfield; Veronique L Roger; John C Burnett; Steven J Jacobsen; Richard J Rodeheffer Journal: JAMA Date: 2011-08-24 Impact factor: 56.272
Authors: Brenda K Huntley; Sharon M Sandberg; Josh A Noser; Alessandro Cataliotti; Margaret M Redfield; Yuzuru Matsuda; John C Burnett Journal: J Cell Physiol Date: 2006-12 Impact factor: 6.384
Authors: Naveen L Pereira; Pinar Aksoy; Irene Moon; Yi Peng; Margaret M Redfield; John C Burnett; Eric D Wieben; Vivien C Yee; Richard M Weinshilboum Journal: J Mol Cell Cardiol Date: 2010-08-06 Impact factor: 5.000
Authors: Rosita Zakeri; James A Levine; Gabriel A Koepp; Barry A Borlaug; Julio A Chirinos; Martin LeWinter; Peter VanBuren; Victor G Dávila-Román; Lisa de Las Fuentes; Prateeti Khazanie; Adrian Hernandez; Kevin Anstrom; Margaret M Redfield Journal: Circ Heart Fail Date: 2015-01 Impact factor: 8.790
Authors: Nicolas Vodovar; Marie-France Séronde; Said Laribi; Etienne Gayat; Johan Lassus; James L Januzzi; Riadh Boukef; Semir Nouira; Philippe Manivet; Jane-Lise Samuel; Damien Logeart; Alain Cohen-Solal; A Mark Richards; Jean-Marie Launay; Alexandre Mebazaa Journal: JACC Heart Fail Date: 2015-08 Impact factor: 12.035
Authors: Laale F Alawi; Sana E Emberesh; Brenda A Owuor; Harshita Chodavarapu; Rucha Fadnavis; Salim S El-Amouri; Khalid M Elased Journal: Physiol Rep Date: 2020-02
Authors: Milton Packer; Carolyn S P Lam; Lars H Lund; Mathew S Maurer; Barry A Borlaug Journal: Eur J Heart Fail Date: 2020-06-26 Impact factor: 15.534
Authors: Suriya Prausmüller; Henrike Arfsten; Georg Spinka; Claudia Freitag; Philipp E Bartko; Georg Goliasch; Guido Strunk; Noemi Pavo; Martin Hülsmann Journal: J Am Heart Assoc Date: 2020-05-19 Impact factor: 5.501
Authors: Suriya Prausmüller; Georg Spinka; Henrike Arfsten; Stefanie Stasek; Rene Rettl; Philipp Emanuel Bartko; Georg Goliasch; Guido Strunk; Julia Riebandt; Julia Mascherbauer; Diana Bonderman; Christian Hengstenberg; Martin Hülsmann; Noemi Pavo Journal: Cells Date: 2021-10-28 Impact factor: 6.600
Authors: Alexandra Petraina; Cristian Nogales; Thomas Krahn; Hermann Mucke; Thomas F Lüscher; Rodolphe Fischmeister; David A Kass; John C Burnett; Adrian J Hobbs; Harald H H W Schmidt Journal: Cardiovasc Res Date: 2022-07-20 Impact factor: 13.081